43rd week of 2014 patent applcation highlights part 39 |
Patent application number | Title | Published |
20140314648 | REMOVAL OF ATMOSPHERIC POLLUTANTS FROM GAS, RELATED APPARATUS, PROCESSES AND USES THEREOF - Methods related generally to the removal of atmospheric pollutants from the gas phase, are provided, as well as related apparatus, processes and uses thereof. A single-stage air scrubbing apparatus is provided that includes at least one reaction vessel, at least one introduction duct, and a turbulence component, wherein a residence time is sufficient to allow the conversion of at least one atmospheric pollution compound to at least one other compound, molecule or atom. In some embodiments, the at least one atmospheric pollution compound comprises nitrogen oxide, sulfur oxide or a combination thereof. Additionally, methods of removing atmospheric pollution compounds from a waste gas stream are disclosed that include introducing a waste gas stream and at least one additional gas stream, mist stream, liquid stream or combination thereof into a single-stage air scrubbing apparatus at a flow rate sufficient to allow for conversion of the at least one atmospheric pollution compound. | 2014-10-23 |
20140314649 | PROCESS FOR REMOVING NITROGEN OXIDES FROM GAS USING MICROWAVE CATALYTIC REACTION BY MICROWAVE CATALYSIS - A method for removing nitrogen-oxides by microwave assisted catalysis, including: 1) charging a catalyst capable of absorbing and interacting with microwave into a reaction tube of a reactor device, to form a reaction bed; and 2) heating the reaction bed by microwaves; when a temperature of the reaction bed is raised to 100-600° C., passing a gas containing nitrogen-oxides through the reaction bed, and performing a gas-solid reaction between the gas and the catalyst to remove the nitrogen-oxides from the gas. | 2014-10-23 |
20140314650 | Processes, Apparatus, Compositions and Systems for Reducing Emissions of HCl and/or Sulfur Oxides - The description relates to reducing emissions of HCl and sulfur oxides by treating combustion gases with an aqueous copper compound referred to as copper-based chloride remediator (CBCR). The process is preferably implemented by identifying locations within a combustor for feeding the CBCR, determining the physical form and injection parameters for the CBCR and injecting the CBCR under conditions effective to reduce HCl and/or sulfur oxides. Effective temperatures for introducing the copper-based chloride remediators are preferably within the range of from about 250° to 900° F. where the objective is to reduce HCl, while temperatures up to about 2200° F. can be employed where the objective is to reduce sulfur oxides. Among the more preferred CBCRs are copper compositions including copper and an ammonia moiety. One composition of this type that was tested was copper diammonium diacetate, which has an empirical formula of C | 2014-10-23 |
20140314651 | Process and Apparatus for Improving the Operation of Wet Scrubbers - The description relates to improving the operation of wet scrubbers, especially those based on calcium carbonate, by reducing the quantities of soluble chlorides in the combustion gases fed to the scrubbers. By converting gaseous HCl in the combustion gases to a solid copper chloride and removing it before the chloride reaches the scrubber, the reactivity of the scrubbing slurry will be better maintained. Combustion gases are treated with an aqueous copper compound referred to as copper-bearing chloride remediator (CBCR). The process is preferably implemented by identifying locations within a combustor for feeding the CBCR, determining the physical form and injection parameters for the CBCR and injecting the CBCR under conditions effective to reduce HCl and/or sulfur oxides. Effective temperatures for introducing the CBCRs are preferably within the range of from about 250° to 900° F. Among the more preferred CBCRs are copper compositions including copper, an organic moiety and/or an ammonia moiety. One composition of this type is copper diamine diacetate, which has an empirical formula of C | 2014-10-23 |
20140314652 | PROCESS FOR CONTINUOUS PRODUCTION OF BORON NITRIDE POWDER - The present invention provides a process for continuously producing crystalline hexagonal boron nitride powder having a large particle size and high crystalline. The present invention relates to a process comprising: the first step of heating a boron-containing material and a nitrogen-containing material to obtain crude boron nitride powder having boron nitride content of 80% by weight or higher, and the second step of feeding the crude boron nitride powder and a boron-containing flux component in the content satisfying the following formula (1) with a heat-resistant container, and heating the container including the crude boron nitride powder and the boron-containing flux component at 1550 to 2400° C. in a continuous furnace under the atmosphere of nitrogen gas, to grow hexagonal boron nitride in the form of crystal: formula (1): boron content contained in boron-containing flux component/crude boron nitride content ≦1.4 % by weight. | 2014-10-23 |
20140314653 | METHOD FOR PREPARATION OF ALUMINUM HYDROXYPHOSPHATE ADJUVANT - The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer. Preferably, an excess of the phosphate solution is used to act as a buffer. Due to the presence of a buffer, the pH is maintained constant during reaction (after initial rapid equilibration) without active adjustment. The methods are particularly applicable for the large scale manufacturing of aluminum phosphate adjuvant. Aluminum phosphate is used as an adjuvant in vaccine formulations, particularly those including a protein or saccharide antigen. | 2014-10-23 |
20140314654 | POLYCRYSTALLINE SILICON ROD AND METHOD FOR PRODUCING POLYSILICON - Polycrystalline silicon rods produced by the Siemens process produce a higher yield of CZ crystals when the process parameters are modified in a second stage of deposition such that an outer layer of larger crystallites having a mean swize>20 μm is produced. Harvesting of these polycrystalline rods and conventional rods by enclosing them in a plastic bag or sheath prior to removal from the reactor also surprisingly increase the yield of CZ crystals grown from a melt containing the sheathed rods. | 2014-10-23 |
20140314655 | CORROSION AND FOULING REDUCTION IN HYDROCHLOROSILANE PRODUCTION - Methods for reducing iron silicide and/or iron phosphide fouling and/or corrosion in a hydrochlorosilane production plant are disclosed. Sufficient hydrogen is added to a silicon tetrachloride process stream to inhibit iron (II) chloride formation and reduce iron suicide and/or iron phosphide fouling, superheater corrosion, or a combination thereof. Trichlorosilane also may be added to the silicon tetrachloride process stream. | 2014-10-23 |
20140314656 | GRAPHENE PRODUCTION METHODS AND RESULTANT PRODUCTS - The present invention relates to a method of mass production of graphene. In one embodiment, such a method may include providing a high temperature furnace for storing a molten solvent, wherein the high temperature furnace comprises an outlet disposed on the top of the high temperature furnace, and an inlet, providing a carbon source to mix with the molten solvent, precipitating the carbon to form a graphene layer on the surface of the molten solvent under a supersaturated state, and collecting the graphene layer from the outlet. | 2014-10-23 |
20140314657 | NUTRIENT RECOVERY SYSTEMS AND METHODS - Methods, systems, and apparatuses for anaerobic digestion of waste fibrous material and the recovery of nutrients are provided. Methods, systems, and apparatuses disclosed herein provide mechanisms to release dissolved gases from anaerobic digester effluent. Methods, systems and apparatuses disclosed herein can recover one or more nutrients from anaerobic digested effluent using a range of temperatures, aeration rates, aeration times, pH ranges, and settling times. | 2014-10-23 |
20140314658 | METHOD OF MANUFACTURING MAGNETIC PARTICLES - The method of manufacturing magnetic particles, wherein the magnetic particles are magnetic particles for magnetic recording, and includes subjecting starting material magnetic particles to glass component-adhering treatment to be adhered with a glass component, and subjecting the magnetic particles after the glass component-adhering treatment to coercive force-reducing treatment with heating, to provide magnetic particles having lower coercive force than the starting material magnetic particles. | 2014-10-23 |
20140314659 | Hydrogen Purification Process - In a process for purifying a hydrogen stream, the stream is contacted with a first washing fluid in a first purification zone under conditions effective to transfer at least some water from the hydrogen stream to the first washing fluid, thereby transforming the hydrogen stream into a water-depleted hydrogen stream. At least a portion of the water-depleted hydrogen stream may then be transferred from the first purification zone to a second purification zone, where it is contacted with a second washing fluid under conditions effective to transfer at least some oxygenates from the water-depleted hydrogen stream to the second washing fluid. | 2014-10-23 |
20140314660 | CHEMICAL IONIZATION WITH REACTANT ION FORMATION AT ATMOSPHERIC PRESSURE IN A MASS SPECTROMETER - The invention relates to the production of water cluster ions (“hydronium clusters”) at atmospheric pressure for the chemical ionization of analyte molecules. It is proposed that a corona discharge at the Taylor cone of an aqueous liquid, preferably pure or slightly acidified pure water, is used instead of corona discharges on metal tips, which have been the usual method up to now. The hydronium clusters of the form [H(H | 2014-10-23 |
20140314661 | Diagnostic System for the Detection of Skin Cancer - Methods and compositions are provided for the analysis of skin surfaces to determine the presence of neoplastic tissue. In the methods of the invention, a composition comprising a florescent probe that binds to a specific neoplasia associated marker is applied topically to the area of interest. After topical administration, the probe preferentially binds to markers associated in neoplastic lesions in situ, which binding is detected with a compact illumination unit that provides illumination at a wavelength appropriate for image acquisition. The illumination unit comprises a light source and fiber optic bundle to direct the light towards the area of examination. A detection unit is used to capture and record an image of the area of investigation. The detection unit may be a digital camera, film camera, etc. A mapping module may also be provided to catalogue the site of examination. | 2014-10-23 |
20140314662 | METHODS AND KITS FOR THE PROGNOSIS OF COLORECTAL CANCER - The invention relates to methods for predicting the risk of relapse of cancer patients as well as methods for providing personalized medicine to said patients based on the expression levels of different genes the expression of which is induced in response to TGF-beta stimulation. The invention also relates to kits for carrying out the diagnostic and predictive medicine methods. | 2014-10-23 |
20140314663 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER - Provided herein are methods for transporting an active agent (e.g., a therapeutic agent or an imaging agent) across the blood-brain barrier (BBB) in a patient. For example, the methods provided herein can be used to treat a brain disease in a patient, such as brain cancer. In some embodiments, the methods provided herein can be used to image the central nervous system of a patient. | 2014-10-23 |
20140314664 | Hydrophobic Molecule-Induced Branched Polymer Aggregates And Their Use - Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy. | 2014-10-23 |
20140314665 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 2014-10-23 |
20140314666 | TARGETED CARRIERS FOR DRUG DELIVERY ACROSS THE GASTROINTESTINAL EPITHELIUM - A system and method for transcellular transport of compositions containing agents (e.g., research, analytical, reporter or molecular probes, diagnostic and therapeutic agents, biologically active agents, research agents, analytical agents, imaging agents, monitoring agents, enzymes, proteins, peptides, nucleic acids, lipids, sugars, hormones, lipoproteins, chemicals, viruses, bacteria, cells, including modified cells, biosensors, markers, antibodies and/or ligands) across the gastrointestinal epithelial layer including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes an anti-ICAM antibody targeting moiety, specific for targeting ICAM-1. The system enables effective, versatile, and safe targeting and transport of agents. The system is useful in research applications, as well as in the context of translational science and clinical interventions. | 2014-10-23 |
20140314667 | METHODS OF TREATING EPIDERMAL GROWTH FACTOR DELETION MUTANT VIII RELATED DISORDERS - The present invention relates to methods of treating treating epidermal growth factor deletion mutant vIII (EGFRvIII) related disorders, such as glioblastoma or anaplastic astrocyte tumors, using antigen binding proteins, including antibodies against EGFRvIII conjugated to a drug. Diagnostic and therapeutic formulations of such antibodies and drug conjugates thereof are also provided. | 2014-10-23 |
20140314668 | TECHNETIUM-99M LABELED COMPLEX OF GOLD NANOPARTICLE-GOLD BINDING PEPTIDES, AND METHOD OF MAKING AND USING THE SAME - There is provided a method for preparing a | 2014-10-23 |
20140314669 | COMPOUNDS FOR BINDING TO THE PLATELET SPECIFIC GLYCOPROTEIN IIB/IIIA AND THEIR USE FOR IMAGING OF THROMBI - The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein 11b/IIIa antagonists for imaging of thrombi. | 2014-10-23 |
20140314670 | CLICKED SOMATOSTATIN CONJUGATED ANALOGS FOR BIOLOGICAL APPLICATIONS - The invention relate to the new conjugated somatostatin analogs of formula (I), wherein A- is H or TAG-B—, wherein —B— is 0 or a spacer, wherein TAG is a chelating agent (e.g. DOTA), a fluorescent dye, (e.g. Bodipy-B derivative, a Rho-damine-B derivative, a Fluorescein-B derivative, a Cyanine-B derivative, a Porphyrin-B derivative), a bimodal agent, or a cytotoxic agent (e.g. a doxorubicin derivative) wherein R1 is CI-C4 alkynyl radical when R2 is CI-C4 azido radical and viceversa and methods for preparing same, pharmaceutical compositions comprising them and their use in imaging and the treatment of cancer. | 2014-10-23 |
20140314671 | PROBES AND METHODS OF IMAGING A BACTERIAL INFECTION - Embodiments of the present disclosure provide for labeled probes such as labeled maltose probes and labeled acarbose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like. | 2014-10-23 |
20140314672 | NANOPARTICLE THERAPEUTIC AGENTS, THEIR FORMULATIONS, AND METHODS OF THEIR USE - Nanoparticle therapeutic agents, formulations that include the nanoparticle therapeutic agents, and methods for treating diseases treatable by the therapeutic agents. | 2014-10-23 |
20140314673 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES - Provided herein are methods for treating or preventing head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression, comprising administering an effective amount of a dihydropyrazino-pyrazine to a patient having head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression. | 2014-10-23 |
20140314674 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES - Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status. | 2014-10-23 |
20140314675 | CANCER STEM CELL ISOLATION - An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same. The present inventors discovered that highly pure colon cancer stem cells (CSC) can be obtained in a large quantity, and identified two types of states of colon CSCs distinguishable through Lgr5 expression. | 2014-10-23 |
20140314676 | METHODS OF TREATMENT WITH DEFERIPRONE - The current application is directed to methods of treating or ameliorating myocardial ischemia, an acute coronary event, and a myocardial reperfusion injury comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient in need thereof. The application is also directed to reducing the risk for myocardial reperfusion injury as well as promoting the beneficial remodeling of cardiac tissue in a patient, comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient before, during or after reperfusion therapy. The application also includes methods of selecting a patient for treatment of reperfusion injury and subsequently treating the selected patient. | 2014-10-23 |
20140314677 | SUBSTITUTED SILAXANTHENIUM RED TO NEAR-INFRARED FLUOROCHROMES FOR IN VITRO AND IN VIVO IMAGING AND DETECTION - The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications. | 2014-10-23 |
20140314678 | COMPOSITIONS AND METHODS USING MICROSPHERES AND NON-IONIC CONTRAST AGENTS - The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed. | 2014-10-23 |
20140314679 | Hypoosmotic Solutions for Lymph Node Detection - Provided are compositions for rapid detection of lymph nodes. The compositions include magnetic particles, such as iron oxide, and a solute present in an amount that results in a hypoosomotic solution. Methods for detecting lymph nodes also are provided. | 2014-10-23 |
20140314680 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof - A dual release oral dosage system/dosage form comprising an immediate release component/composition and a delayed release component/composition is described. Each of the immediate release component/composition and delayed release component/composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and/or a salt of the metabolite. The dual release oral dosage system/dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP). | 2014-10-23 |
20140314681 | POLY-HAPTEN WITH TOPICAL HORMONE ALOPECIA HAIR REGROWTH SYSTEM - A hair regrowth system consisting of sensitization, growth, and maintenance kits for alopecia areata and related alopecia balding conditions. Graduated doses of specific engineered and or extracted haptens are included in a sensitization kit for initiating immune system response in hairless areas. A growth kit containing topical hormones to increase papilla size and vigor and a maintenance kit to sustain immune system response and papilla size and vigor for the long term are included in some embodiments. | 2014-10-23 |
20140314682 | COLOR CHANGE OF CHALCONE-CONTAINING ORAL CARE FORMULATIONS - Oral care compositions and methods are described in which the composition includes a chalcone color change component, which may be phenyl-3-methoxy-4-hydroxystyryl ketone. The color change component is induced to change colors by addition of saliva and/or by a change in pH of the composition. The composition and methods provide benefits including providing visual cues to the user. | 2014-10-23 |
20140314683 | Mineral, Nutritional, Cosmetic, Pharmaceutical, And Agricultural Compositions And Methods For Producing The Same - Mineral, cosmetic, pharmaceutical, agricultural, nutraceutical, and other compositions are produced using a mineral composition containing minimal concentrations of cadmium, lead, arsenic, and mercury and containing relatively high concentrations of micro and macro mineral elements, of rare earth elements, of calcium, and of silica. The mineral concentrations are produced by processing naturally occurring clay soil to concentrate mineral elements naturally occurring in the soil. | 2014-10-23 |
20140314684 | MEDICINAL AEROSOL FORMULATIONS - The present invention provides a process for making a stabilized medical aerosol suspension formulation for administration by a pressurized metered dose inhaler. | 2014-10-23 |
20140314685 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 2014-10-23 |
20140314686 | POLYPHENOL/FLAVONOID COMPOSITIONS AND METHODS OF FORMULATING ORAL HYGIENIC PRODUCTS - Microemulsions and soluble alkali metal salts of relatively insoluble aglycone polyphenols within oral hygienic products are disclosed for treating oral inflammatory disorders. The formulations can act as a bactericide or bacteriostat. The methods include the process associated with the formation of a high temperature polyphenol/surfactant concentrate, a nano-particulate precipitation process in the presence of a surfactant and the solubilization of relatively insoluble aglycone polyphenols/flavonoids by the formation of soluble alkali metal salts within alkaline oral compositions. | 2014-10-23 |
20140314687 | NON-ALCOHOL MOUTHWASH COMPOSITION WITHOUT CHEMICAL ANTIBACTERIAL MEDICAMENT - A non-alcohol mouthwash composition without chemical antibacterial medicament is disclosed. The non-alcohol mouthwash composition includes from 0.03% to 1.5% of γ-polyglutamic acid (γ-PGA) and from 0.5% to 4% of surfactant, all percentages based on the total weight of the mouthwash composition. The non-alcohol mouthwash composition preferably includes from 0.4% to 1.5% by weight, or more preferably from 0.8% to 1.3% by weight, of γ-PGA. Containing no chemical antibacterial medicament, the non-alcohol mouthwash composition can effectively inhibit bacterial growth in the oral cavity without irritating the oral mucosa. | 2014-10-23 |
20140314688 | ORAL CARE COMPOSITIONS - Oral care compositions comprising isobutyl magnolol and n-butyl magnolol. A method of enhancing the solubility of isobutyl magnolol in an oral care composition comprises admixing n-butyl magnolol with an orally acceptable carrier comprising isobutyl magnolol. The composition may be used to treat diseases or conditions of the oral cavity such as caries, gingivitis, periodontitis, tooth yellowing and halitosis. | 2014-10-23 |
20140314689 | THYMOL AND TOTAROL ANTIBACTERIAL COMPOSITION - An antibacterial composition comprising thymol and totarol. This combination provides synergistic effect against gram negative and gram positive bacteria. | 2014-10-23 |
20140314690 | ORAL CARE COMPOSITIONS - Described herein are preservative systems which prevent the growth of microorganisms in silica based dentifrices, compositions comprising the same; and methods of making and using the same. | 2014-10-23 |
20140314691 | COMPOSITIONS FOR IMPROVING THE APPEARANCE AND/OR HEALTH OF TEETH - In various embodiments compositions are provided for the whitening, and/or brightening, and/or restoration of a tooth. In various embodiments the compositions, referred to herein as “dental care” compositions typically comprise a binding moiety that binds to calcium and/or to tooth enamel and/or to pellicle attached to an active agent. The active agent is selected to deliver a particular activity (e.g., whitening, remineralization, desensitization, brightening, etc.) to the tooth. | 2014-10-23 |
20140314692 | Thin Film Toothpaste Strip - A non-adhering oral tape, film or strip home oral care composition includes a cleansing effective amount of a teeth cleaning agent and a fluoridating effective amount of a fluoridating agent; to methods of forming or using these non-adhering oral tapes, films or strips, and particularly to non-adhering oral tapes, films or strips containing precise dosage amounts of fluoride. Precision fluoride dosage can help mitigate the inherent problems of fluoride over dosage associated with standard dentifrice formulations. The present disclosure is also directed to kits for home use containing these non-adhering oral tapes, films or strips. | 2014-10-23 |
20140314693 | ORAL CARE WHITENING COMPOSITIONS - Described herein are whitening compositions comprising a peroxide source, and an adhesion system comprising a hydrophobic component comprising a silicone adhesive; and a dental surface adhesion enhancing agent, which are physically stable and effectively provide whitening. Methods of making and using these compositions are also described herein. | 2014-10-23 |
20140314694 | DESENSITIZING TOOTHPASTE - The present invention discloses a desensitizing toothpaste. Based on the total weight of the desensitizing toothpaste, the desensitizing toothpaste includes: from 5% to 40% by weight of DP-bioglass; from 1% to 5% by weight of thickening agents; from 25% to 35% by weight of humectant; and from 1% to 5% by weight of surfactant, wherein the DP-bioglass includes: 8.4% of Na | 2014-10-23 |
20140314695 | SILICONE SCAR TREATMENT PREPARATION - Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives. | 2014-10-23 |
20140314696 | COSMETIC COMPOSITION COMPRISING AT LEAST ONE ALKOXYSILANE - The present invention relates to a cosmetic or dermatological composition of sol/gel type for making up and/or caring for keratin materials characterized in that it comprises the product resulting from the reaction: (a) of at least one alkoxysilane monomer or oligomer of formula (I) R1xSi(OR2)(4-x) or of formula (II) [R1y (OR2)z SiO ((4-γ-ζ)]η in which R1 represents, independently, a nucleophilic group other than a hydroxyl, or a (Ci-C2o)alkyl group, R2 represents, independently, a (Ci-Cio)alkyl group, and (b) of an amount of water corresponding to a number of moles of water, determined according to the following equation: X−(llAlkoxysilanes×llbAlkoxy groups)/nH2o with nH2o=Number of moles of water, nAikoxysiianes=Number of moles of alkoxysilane compounds, nbAikoxy groups=Weighted mean of the number of alkoxysilane groups per alkoxysilane compound, and X is a number greater than 2. It also relates to an associated cosmetic process and an associated kit for coating keratin materials. | 2014-10-23 |
20140314697 | Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof - This invention discloses method for inhibiting inflammation and reducing melanophilin expression with glycine derivatives and the composition thereof. The mentioned glycine derivatives can not only efficiently inhibit skin inflammation, but also can present significant melanophilin expression reduction. This mentioned composition of this invention comprises the glycine derivatives, and shows melanophilin expression reduction and anti-inflammatory effect. The mentioned composition can be applied in topical cosmetic or pharmaceutical compositions as skin care preparations, or functional preparations. | 2014-10-23 |
20140314698 | ALDEHYDE DEHYDROGENASE INHIBITORS AS NOVEL DEPIGMENTING AGENTS - The present invention provides methods and compositions for reducing pigmentation. | 2014-10-23 |
20140314699 | PERFUMING INGREDIENTS OF THE FLORAL AND/OR ANIS TYPE - The present invention concerns a compound of formula | 2014-10-23 |
20140314700 | ANTIPERSPIRANT ACTIVE COMPOSITIONS AND MANUFACTURE THEREOF - An antiperspirant active composition comprising an aluminum salt, the aluminum salt (i) having an aluminum to chloride molar ratio of 0.3:1 to 3:1; and (ii) having a species of polyhydroxyoxoaluminum cation detectable at 76 ppm by | 2014-10-23 |
20140314701 | ANHYDROUS LIQUID ANTIPERSPIRANT COMPOSITION - An anhydrous liquid antiperspirant composition comprising a carrier comprising a cation and/or zwitterion and a hydrogen bond donor, wherein an amount of carrier is greater than an amount of any other material in the composition, and an antiperspirant active. This represents a new delivery form for antiperspirant actives and/or deodorant actives. | 2014-10-23 |
20140314702 | COMPOSITION - Hair conditioning composition comprising: —from 0.1 to 10% wt. silicone —from 0.1 to 5% wt. metal pyrithione blended with non-anionic surfactant. | 2014-10-23 |
20140314703 | IMMUNOGENIC COMPLEXES OF POLYANIONIC CARBOMERS AND ENV POLYPEPTIDES AND METHODS OF MANUFACTURE AND USE THEREOF - The present invention relates to immunogenic complexes formed between polyanionic carbomers and Env polypeptides. Uses of the immunogenic complexes in applications including inducing an immune response and immunization generally are described. Methods of forming and manufacture of the immunogenic complexes are also described. The present invention also relates to immunogenic compositions including low viscosity, polyanionic carbomers and Env polypeptides. Uses of such immunogenic compositions in applications including inducing an immune response and immunization generally are described. Methods of manufacture of such immunogenic compositions are also described. | 2014-10-23 |
20140314704 | Treatment of B Cell Lymphomas - Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided. | 2014-10-23 |
20140314705 | THERMORESPONSIVE COMPOSITIONS FOR DERMATOLOGICAL USE AND METHODS THEREOF - The present specification generally relates to compositions comprising a thermoresponsive polymer and methods of treating a soft tissue condition using such compositions. | 2014-10-23 |
20140314706 | ADVANCED FUNCTIONAL BIOCOMPATIBLE POLYMER PUTTY USED AS A HEMOSTATIC AGENT FOR TREATING DAMAGED TISSUE AND CELLS - A hemostatic putty for treatment of a variety of wounds topographies, including but not limited to highly three dimensional wounds, for example gunshot wounds and impalements, is disclosed. The putty is comprised of a matrix polymer weakly crosslinked or not crosslinked such that a viscoelastic matrix is formed. The viscoelastic nature of the putty is tunable by the composition and enables the putty to conform to a variety of wound topographies. Likewise, a hemostatic polymer, for example chitosan or hydrophobically modified chitosan, is included in this matrix to impart hemostatic properties and tissue adhesive on the putty. The hemostatic polymers disclosed prevent microbial infection and are suitable for oxygen transfer required during normal wound metabolism. | 2014-10-23 |
20140314707 | Immunostimulating Polyphosphazene Compounds - Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed. | 2014-10-23 |
20140314708 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 2014-10-23 |
20140314709 | IL-2 DERIVATIVES POLYPEPTIDES WITH AGONIST ACTIVITY FOR THERAPY OF CANCER AND CHRONIC INFECTIONS - The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases. | 2014-10-23 |
20140314710 | IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment - A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p40 | 2014-10-23 |
20140314711 | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE - The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof. | 2014-10-23 |
20140314712 | FUSION PROTEIN COMPRISING AN INTERLEUKIN 4 AND INTERLEUKIN - The invention is concerned with a fusion protein comprising interleukin 10 and interleukin 4, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of osteoarthritis, chronic pain, a condition characterized by local or systemic inflammation, immune activation, and/or lymphoproliferation. | 2014-10-23 |
20140314713 | METHODS FOR DETERMINING TREATMENT RESPONSE IN PATIENTS INFECTED WITH HCV GENOTYPE 4 - The present invention relates to a method for testing whether a patient infected with HCV genotype 4 could achieve a sustained virological response (SVR) to the combination of interferon-alpha and ribavirin comprising determining the patient's genotype for the single nucleotide polymorphism rs 12979860 wherein the presence of the better response allele C indicates a high chance to achieve a sustained virological response (SVR) and the presence of the allele T indicates a lower chance to achieve a sustained virological response (SVR). | 2014-10-23 |
20140314714 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection. | 2014-10-23 |
20140314715 | Compositions and Methods for Diagnosing and Treating Sjogren's Syndrome - Methods for detection and diagnosis of Sjögren's Syndrome in a subject, determining the stage or progression of Sjögren's Syndrome in a subject, determining the effectiveness of a treatment for Sjögren's Syndrome, and selecting a subject for treatment for Sjögren's Syndrome are disclosed. The methods typically include measuring the level of one or more Sjögren's Syndrome biomarkers in a biological sample obtained from a subject. Biomarkers for Sjögren's Syndrome include, but are not limited to, GADD153 and Del-1. | 2014-10-23 |
20140314716 | PROTEASE-DEFICIENT BACILLUS ANTHRACIS - The invention relates to a | 2014-10-23 |
20140314717 | SIMIAN (GORILLA) ADENOVIRUS OR ADENOVIRAL VECTORS AND METHODS OF USE - The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein. | 2014-10-23 |
20140314718 | NEW STRAIN OF BACILLUS SUBTILIS FOR COMBATING PLANT DISEASES - The present invention relates to an isolated strain of | 2014-10-23 |
20140314719 | IBS Treatment - The invention relates to treatment of Irritable Bowel Syndrome using probiotic preparations containing viable, metabolically active probiotic bacteria. | 2014-10-23 |
20140314720 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF - Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl)4′,5′-dichloro-benzoic acid methyl ester hydrochloride. | 2014-10-23 |
20140314721 | USE OF NEURAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject. | 2014-10-23 |
20140314722 | MATRICES COMPRISING A MODIFIED POLYSACCHARIDE - The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group. | 2014-10-23 |
20140314723 | ENDOTHELIAL CELL CULTURE - The disclosure relates to cell culture vessels comprising fabricated cell culture surfaces providing means for efficient corneal endothelial cell growth and the use of the cultured cells in the repair of corneal tissue damage. | 2014-10-23 |
20140314725 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS - The present invention provides a method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells from induced pluripotent stem cells. With the method, embryoid bodies are first formed from induced pluripotent stem cells in a non-adherent substrate. The embryoid bodies are then contacted with a serum-free and insulin-free medium comprising a p38-MAPK inhibitor to form aggregates of contracting embryoid bodies. The contracting embryoid body aggregate(s) are then induced to form mesenchymal stem-cell-like cells and aggregates of cardiomyocyte-like stem cells with a medium comprising ≦5% serum in a cell-culture treated substrate. The cardiomyocyte-like cells and the mesenchymal stem-cell like cells may be separated to give isolated populations of each cell type. The population of cardiomyocyte-like cells and mesenchymal stem-cell like cells and the isolated population of each cell type may be used for replacing cells. In particular, the cells may be used for replacing cells in cardiac repair and/or cardiac therapy. | 2014-10-23 |
20140314726 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - The present invention concerns methods and compositions for differentiating cells, including human fibroblasts, into chondrocyte-like cells via in vivo mechanical strain. In particular aspects, fibroblasts are delivered to a joint, such as an intervertebral disc, following which the fibroblasts differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. The fibroblasts that do not differentiate to chondrocytic cells because of the location of the cells, as in the fissures of annulus, or other biomechanical and biochemical micro-environment factors, may produce fibrous matrix molecule(s) in aiding tissue repair and regeneration in both nucleus pulposus and annulus fibrosus. In certain aspects, the fibroblasts prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 2014-10-23 |
20140314727 | SYNTHESIS OF LONG-CHAIN POLYUNSATURATED FATTY ACIDS BY RECOMBINANT CELL - The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids. | 2014-10-23 |
20140314728 | 2-HYDROXYGLUTARATE AS A BIOMARKER FOR CHRONIC HYPOXIA - The present invention provides biomarkers for sensitive, specific, accurate and quantitative diagnosis and assessment of chronic hypoxia. In particular, the present invention provides 2-hydroxyglutarate as a biomarker that is differentially produced in chronic hypoxia. Furthermore, embodiments of the invention are able to differentiate between chronic and acute hypoxia. Assays for levels of 2-hydroxyglutarate may be used alone or in conjunction with additional biomarkers of hypoxia to increase the precision of analysis. In particular embodiments of the invention, the level of 2-hydroxyglutarate and at least one second biomarker may be assayed to generate a hypoxic profile that can be compared to a reference or control profile, thereby diagnosing a subject as normoxic, chronically hypoxic, or acutely hypoxic. | 2014-10-23 |
20140314729 | NUTRACEUTICAL FORMULATION FOR TREATMENT OF ELEVATED CHOLESTEROL AND CARDIOVASCULAR DISEASE - Disclosed are compositions of matter useful for the treatment of elevated blood cholesterol. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: policosanol, niacin, guggul, garlic, | 2014-10-23 |
20140314730 | COMPOSITION AND METHODS FOR RELIEF OF CHEMICAL SENSITIVITY - The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water. | 2014-10-23 |
20140314731 | COMPOSITION FOR PROTECTION AGAINST CELL-DAMAGING EFFECTS - The present invention relates to a composition consisting of Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin. The present invention relates further to the use of the composition for minimizing the cell-damaging effect of radicals and harmful forms of oxygen, in particular of oxygen radicals or reactive oxygen species. The present invention relates to a composition comprising Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin, wherein the composition is administered in a concentration ranging from 10 to 20 mg/kg body weight. The present invention relates further to the composition for use in the treatment and/or prevention of radical and harmful forms of oxygen derived diseases, in particular of oxygen radical or reactive oxygen species derived diseases. The present invention relates further to the composition as a food supplement or dietary supplement. | 2014-10-23 |
20140314732 | CROSS-LINKED COMPOSITIONS - Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG). | 2014-10-23 |
20140314733 | Product and Method for the Removal of Biofilms - Composition for the removal of biofilms present on a substrate, comprising at least one detergent component comprising at least one sequestering agent and at least one agent that is simultaneously a wetting and a dispersing agent, and at least one enzymatic component containing at least one protease, at least one laccase and at least one polysaccharidase | 2014-10-23 |
20140314734 | COMPOSITIONS AND METHODS FOR SPECIFIC REGULATION OF PYRUVATE DEHYDROGENASE KINASE - A peptide composition is provi'deo!which specifically inhibits the ability of δ protein kinase C (δPKC) to phosphor/late pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion. | 2014-10-23 |
20140314735 | PROCESS FOR CONCENTRATION OF A POLYPEPTIDE - The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such a concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection. | 2014-10-23 |
20140314736 | NOVEL PATIENT SUBGROUPS FOR THROMBOLYSIS - A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and/or an absolute “mismatch volume”. | 2014-10-23 |
20140314737 | Blood Biomarker for Early Blood Brain Barrier Disruption in Ischemic Stroke - Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample. | 2014-10-23 |
20140314738 | DISINFECTING COMPOSITION - A disinfecting composition comprises chitosan and peroxycarboxylic acid. The weight ratio of chitosan to peroxycarboxylic acid is from 0.01-100. Chitosan is selected from the group consisting of amino monosaccharide, acetylamino monosaccharide, chitooligosaccharide, chitosan polymer and the combination thereof, and peroxycarboxylic acid is a C1-C18 aliphatic peroxycarboxylic acid that is selected from the group consisting of peroxy monocarboxylic acid, peroxy dicarboxylic acid and the combination thereof. | 2014-10-23 |
20140314739 | Vaccine adjuvant composition comprising inulin particles - The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine. Also provided is a single-dose vaccine composition comprising inulin particles, an antigen and, optionally, an antigen-binding carrier material, and methods and uses of the vaccine. | 2014-10-23 |
20140314740 | COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF DIABETIC COMPLICATIONS - The invention provides compositions and methods for the prevention, amelioration, and/or treatment of diabetes complications, including ocular diseases associated with increased glucose transport and/or oxidative stress. | 2014-10-23 |
20140314741 | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases - FLB5M5 is a humanized monoclonal antibody with three mutated amino acids in the CDRs relative to its parental mouse anti-IL-20 monoclonal antibody 7E and five mutated amino acids of the light-chain framework region relative to the amino acids of the light-chain framework region of human Vκ2. FLB5M5 not only retains binding specificity toward IL-20 but also has a better binding affinity than 7E for IL-20. FLB5M5 is also less immunogenic than 7E to the human host in clinical application. A mutation in the light chain CDR to tyrosine increases binding affinity to IL-20. A method for treating rheumatoid arthritis using FLB5M5 is also disclosed. | 2014-10-23 |
20140314742 | ENDOGLIN ANTIBODIES - The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof. | 2014-10-23 |
20140314743 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL17-A/F AND POLYPEPTIDES COMPRISING THE SAME - The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 2014-10-23 |
20140314744 | MCAM ANTAGONISTS AND METHODS OF TREATMENT - Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin α4 chain, e.g., an α4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS. | 2014-10-23 |
20140314745 | METHODS TO CONTROL PROTEIN HETEROGENEITY - The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells. | 2014-10-23 |
20140314746 | METHODS FOR TREATING OR PREVENTING FIBROSIS IN SUBJECTS AFFLICTED WITH SCLERODERMA - The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject. | 2014-10-23 |
20140314747 | PREDICTING RESPONSE TO EGFR INHIBITORS - Methods of predicting whether a cancer will respond to an EGFR inhibitor are provided. | 2014-10-23 |
20140314748 | ANTIBODY FORMULATIONS - The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations. | 2014-10-23 |